Ilic M, Ilic I (2016) Epidemiology of pancreatic cancer. World J Gastroenterol 22(44):9694–9705. https://doi.org/10.3748/wjg.v22.i44.9694

Article  PubMed  PubMed Central  Google Scholar 

Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825. https://doi.org/10.1056/NEJMoa1011923

Article  CAS  PubMed  Google Scholar 

Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703. https://doi.org/10.1056/NEJMoa1304369

Article  CAS  Google Scholar 

Ozaka M, Ishii H, Sato T et al (2018) A phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81(6):1017–1023. https://doi.org/10.1007/s00280-018-3577-9

Article  CAS  PubMed  Google Scholar 

Mie T, Sasaki T, Takeda T et al (2021) Comparison of treatment outcomes between gemcitabine with nab-paclitaxel and modified FOLFIRINOX for first-line chemotherapy in metastatic and recurrent pancreatic cancer: propensity score matching. Pancreas 50(4):595–601. https://doi.org/10.1097/MPA.0000000000001801

Article  CAS  PubMed  Google Scholar 

Ohba A, Ueno H, Shiba S et al (2022) Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: a multicenter phase 1b dose-escalation and dose-expansion clinical trial. Eur J Cancer 174:40–47. https://doi.org/10.1016/j.ejca.2022.06.010

Article  CAS  PubMed  Google Scholar 

Ohba A, Ozaka M, Ogawa G et al (2023) 1616O nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicentred, randomized, open-label, three-arm, phase II/III trial. Ann Oncol 34:S895–S924. https://doi.org/10.1016/j.annonc.2023.09.2565

Article  Google Scholar 

Kasuga A, Hamamoto Y, Takeuchi A et al (2018) Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis. Invest New Drugs 36(5):939–948. https://doi.org/10.1007/s10637-018-0589-6

Article  CAS  PubMed  Google Scholar 

McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67(3):257–262. https://doi.org/10.1017/S0029665108007131

Article  PubMed  Google Scholar 

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244

Article  CAS  PubMed  Google Scholar 

Wainberg ZA, Melisi D, Macarulla T et al (2023) NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402(10409):1272–1281. https://doi.org/10.1016/S0140-6736(23)01366-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Portal A, Pernot S, Tougeron D et al (2015) Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer 113(7):989–995. https://doi.org/10.1038/bjc.2015.328

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chae H, Jeong H, Cheon J et al (2020) Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Ther Adv Med Oncol 12:1758835920923424. https://doi.org/10.1177/1758835920923424

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mie T, Sasaki T, Takeda T et al (2023) Treatment outcomes and prognostic factors of gemcitabine plus nab-paclitaxel as second-line chemotherapy after modified FOLFIRINOX in unresectable pancreatic cancer. Cancers (Basel). https://doi.org/10.3390/cancers15020358

Article  PubMed  Google Scholar 

Wang-Gillam A, Hubner RA, Siveke JT et al (2019) NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 108:78–87. https://doi.org/10.1016/j.ejca.2018.12.007

Article  CAS  PubMed  Google Scholar 

Sawada M, Kasuga A, Mie T et al (2020) Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer 20(1):449. https://doi.org/10.1186/s12885-020-06945-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mie T, Sasaki T, Okamoto T et al (2022) Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. Jpn J Clin Oncol 52(12):1399–1407. https://doi.org/10.1093/jjco/hyac145

Article  PubMed  Google Scholar 

Tezuka S, Ueno M, Kobayashi S et al (2022) Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: a single center retrospective study. Pancreatology 22(6):789–796. https://doi.org/10.1016/j.pan.2022.06.004

Article  PubMed  Google Scholar 

Park HS, Kang B, Chon HJ et al (2021) Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). ESMO Open 6(2):100049. https://doi.org/10.1016/j.esmoop.2021.100049

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zaibet S, Hautefeuille V, Auclin E et al (2022) Gemcitabine + nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Br J Cancer 126(10):1394–1400. https://doi.org/10.1038/s41416-022-01713-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hino K, Nishina T, Numata Y et al (2022) Clinical outcomes of S-1 monotherapy and modified FOLFIRINOX therapy after gemcitabine plus nab-paclitaxel therapy in unresectable pancreatic cancer. Intern Med 61(15):2255–2261. https://doi.org/10.2169/internalmedicine.8736-21

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ikezawa K, Kiyota R, Takada R et al (2021) Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer. JGH Open 5(6):679–685. https://doi.org/10.1002/jgh3.12555

Article  PubMed  PubMed Central  Google Scholar 

Fukahori M, Okabe Y, Shimokawa M et al (2023) Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Sci Rep 13(1):19399. https://doi.org/10.1038/s41598-023-46924-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imaoka H, Ikeda M, Kobayashi S et al (2024) Efficacy of liposomal irinotecan + 5-FU/LV vs S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting. J Gastroenterol. https://doi.org/10.1007/s00535-024-02186-9

Article  PubMed  PubMed Central  Google Scholar